热门资讯> 正文
波士顿科学公司完成收购Axonics
2024-11-15 22:21
- Boston Scientific (NYSE:BSX) announced the close of its acquisition of Axonics (NASDAQ:AXNX), a medical technology company focused on the development and commercialization of differentiated devices to treat urinary and bowel dysfunction.
- The purchase price of $71 cash per share represents an equity value of $3.7B and an enterprise value of $3.3B.
- The transaction is expected to be immaterial to adjusted earnings per share in 2024 and 2025 and accretive thereafter.
- On a GAAP basis, the transaction is expected to be less accretive, or more dilutive, due to amortization expense and acquisition-related charges.
- Source: Press Release
More on Boston Scientific
- Axonics' Market Growth Strengthens Boston Scientific's Future
- Boston Scientific Corporation (BSX) Business Update Earnings Call Transcript
- Business Update
- Boston Scientific to acquire AFib ablation tech firm Cortex
- Boston Scientific ACURATE neo2 aortic valve misses primary endpoint in trial
推荐文章
港股周报 | 中国大模型“春节档”打响！智谱周涨超138%；巨亏超230亿！美团周内重挫超10%
一周财经日历 | 港美股迎“春节+总统日”双假期！万亿零售巨头沃尔玛将发财报
一周IPO | 赚钱效应持续火热！年内24只上市新股“0”破发；“图模融合第一股”海致科技首日飙涨逾242%
从软件到房地产，美国多板块陷入AI恐慌抛售潮
Meta计划为智能眼镜添加人脸识别技术
危机四伏，市场却似乎毫不在意
美股机会日报 | 降息预期升温！美国1月CPI年率创去年5月来新低；净利、指引双超预期！应用材料盘前涨超10%
财报前瞻 | 英伟达Q4财报放榜在即！高盛、瑞银预计将大超预期，两大关键催化将带来意外惊喜？
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
